AC
GSK icon

AlphaCore Capital’s GSK GSK Stock Holding History

AlphaCore Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Buy
11,090
+518
+5% +$27.4K 0.01% 620
2026
Q1 		$588K Sell
10,572
-10,646
-50% -$577K 0.01% 505
2025
Q4 		$1.05M Sell
21,218
-582
-3% -$27.1K 0.02% 408
2025
Q3 		$950K Buy
21,800
+8,807
+68% +$344K 0.03% 311
2025
Q2 		$505K Buy
12,993
+2,386
+22% +$91.2K 0.02% 368
2025
Q1 		$415K Buy
10,607
+590
+6% +$21.6K 0.04% 302
2024
Q4 		$339K Sell
10,017
-3,626
-27% -$131K 0.07% 159
2024
Q3 		$563K Sell
13,643
-465
-3% -$19K 0.13% 108
2024
Q2 		$548K Buy
14,108
+467
+3% +$19.6K 0.13% 98
2024
Q1 		$590K Buy
13,641
+17
+0.1% +$701 0.16% 87
2023
Q4 		$511K Sell
13,624
-2,713
-17% -$97.4K 0.07% 140
2023
Q3 		$592K Buy
16,337
+1
+0% +$35 0.09% 132
2023
Q2 		$582K Buy
+16,336
New +$586K 0.09% 131
2020
Q2 		– Sell
-98
Closed -$5K – 173
2020
Q1 		$5K Buy
+98
New +$5.23K ﹤0.01% 254

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AlphaCore Capital's GSK Position: Q2 2026 in Review

AlphaCore Capital increased its GSK (GSK) stake by 4.9% in Q2 2026, buying an estimated $27.4K and bringing the position to 11,090 shares worth $581K. The position accounts for 0.01% of the portfolio, ranked #620.

AlphaCore Capital first reported a position in GSK in Q1 2020 and has held it in 14 quarters since. The position peaked at $1.05M in Q4 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • AlphaCore Capital held 11,090 shares of GSK worth $581K as of Q2 2026.
  • AlphaCore Capital bought 518 GSK shares in Q2 2026, an estimated $27.4K.
  • GSK made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #620 holding.
  • AlphaCore Capital first reported a position in GSK in Q1 2020 and has held it in 14 quarters since.
  • AlphaCore Capital's GSK position peaked at $1.05M in Q4 2025.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.